Login to Your Account



Opdivo-Yervoy combo shows mixed results in kidney cancer

By Michael Fitzhugh
Staff Writer

Wednesday, August 16, 2017

A combination of the Bristol-Myers Squibb Co. checkpoint inhibitors Opdivo and Yervoy diminished the size of previously untreated RCC for more people than Pfizer Inc.'s Sutent during a closely watched phase III trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription